Cancers are composed of multiple cell types, including fibroblasts and epithelial cells;innate and adaptive immune cells;and cells forming blood and lymphatic vasculature;as well as specialized mesenchymal cell-types unique to each tissue microenvironment. While tissue homeostasis is maintained by collaborative interactions between these diverse cell types, cancer development is enhanced when genetically altered initiated cells harness these collaborative capabilities to favor their own survival and, in so doing, hijack or exploit normal physiological processes typically involved in maintaining tissue homeostasis. While previously supporting research programs focused solely on cancer and immunity, the expanded Cancer, Immunity, and the Microenvironment Program (Program) now supports research programs revealing insights into the interactions between evolving neoplastic cells with activated non-neoplastic host cells, and with soluble or insoluble components of extracellular matrix, as well as studies based on these interactions that foster development of novel cellular or molecular-based strategies to combat cancer. Specific scientific goals of the Program include: (1) to explore the relationship between neoplastic cells and stromal cells (i.e., immune, vascular, and mesenchymal) in mouse models of cancer to gain insights into the ability of stromal cells in the tumor microenvironment to promote or deter tumorigenesis;(2) to identify molecules and pathways in the tumor microenvironment that regulate anti-tumor activity;(3) to study the relationship between viral infections and malignancy, particularly in immunodeficient patients with HIV infection, and to develop new approaches for the prevention and treatment of malignancy in this population;and (4) to provide the basic scientific foundation and support for the application of new immune- or microenvironment-based therapeutics in cancer in conjunction with the organ-based Helen Diller Family Comprehensive Cancer Center (Center) Programs. With these expanded goals, the retooled Program grew to 27 faculty representing 13 departments in the School of Medicine. Faculty in the new Cancer, Immunity, and the Microenvironment Program are supported by $16,323,690 in NCI and other peer-reviewed grants per year, and published 612 scientific articles in the previous funding cycle. The Program has 6% intra-programmatic and 21% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693933
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$143
Indirect Cost
$53
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications